14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs NVO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas NVO carries 41.8/100 (SELL) at $41.71 (12.2x Forward P/E, 50.8% operating margin).
Defensive Composite Rating Caution: Although NVO compares more favorably head-to-head, both NVS (41.5/100 SELL) and NVO (41.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs NVO. Trailing 12-month operating profitability (NVS 34.0% vs NVO 50.8%) and valuation multiples (NVS 16.2x vs NVO 12.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
NVO Moat ProfileHigh-Margin Pricing Power Moat
Global GLP-1 Diabetes & Obesity Biologics Leader
Operates vertically integrated peptide fermentation and auto-injector supply chains serving global diabetes and weight-management markets.
OpEx & R&D Reinvestment32.5% of Rev ($16.7B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs NVO Key Questions & Quantitative Answers
As of Nov 16, 2026, Novo-Nordisk A/S (NVO) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas NVO carries 41.8/100 (SELL) at $41.71 (12.2x Forward P/E, 50.8% operating margin). Defensive Composite Rating Caution: Although NVO compares more favorably head-to-head, both NVS (41.5/100 SELL) and NVO (41.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
NVO leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with NVO at +5.6% YoY revenue growth and -15.8% YoY earnings growth on $51.5B TTM revenue (83.3% gross margin, 50.8% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $51.5B for NVO. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 32.5% of Rev ($16.7B) (0 disclosures) for NVO.
NVO screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas NVO trades at 12.2x Forward P/E, 10.3x Trailing P/E, 4.21x PEG, and 3.8x EV/Revenue (13.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus NVO (58.4% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, NVO carries 32.5% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.50β · 32% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.